肝内胆管癌外科治疗研究焦点及分型治疗策略

李斌

中国实用外科杂志 ›› 2026, Vol. 46 ›› Issue (4) : 472-479.

PDF(1346 KB)
PDF(1346 KB)
中国实用外科杂志 ›› 2026, Vol. 46 ›› Issue (4) : 472-479. DOI: 10.19538/j.cjps.issn1005-2208.2026.04.15
专家论坛

肝内胆管癌外科治疗研究焦点及分型治疗策略

作者信息 +

Research focus and subtype-specific treatment strategies for surgical treatment of intrahepatic cholangiocarcinoma

Author information +
文章历史 +

摘要

外科治疗是肝内胆管癌目前最有效的治疗手段,聚焦肝内胆管癌关键性不良生物学机制建立外科分型及治疗策略对提高肿瘤根治性切除率、改善预后至关重要。在肿瘤微环境中癌症相关成纤维细胞和肿瘤相关巨噬细胞与神经髓鞘施万细胞之间的串扰影响下,肝内胆管癌易侵犯神经和淋巴结转移,而肝门区域大肝蒂的Glisson 鞘的解剖学特点会强化上述肿瘤不良生物学行为。肝门区域Ⅱ级大胆管支起源胆管癌和肝内小胆管支起源、但已侵犯至肝门区域大肝蒂Glisson 鞘的胆管癌,具有相近的肿瘤解剖学和生物学特点,将二者定义为中央型肝内胆管癌,以区别于无上述病理解剖学特点的外周型肝内胆管癌,有利于临床开展同质化研究、建立更为有效的外科治疗体系。

Abstract

Surgical treatment is the most effective therapeutic approach for intrahepatic cholangiocarcinoma. Establishing surgical classification and treatment strategies based on key adverse biological mechanisms of the disease is crucial for increasing the rate of curative resection and improving prognosis. Under the crosstalk effects between cancer-associated fibroblasts and tumor-associated macrophages in the tumor microenvironment and Schwann cells of the nerve myelin sheath,intrahepatic cholangiocarcinoma readily invades nerves and metastasizes via lymphatic routes. The anatomical characteristics of Glisson’s capsule enveloping the large hepatic pedicle in the liver hilar region exacerbate these adverse biological behaviors of the tumor. Cholangiocarcinoma originating from secondary branches of the intrahepatic bile duct system and originating from small intrahepatic bile duct branches but invading the large hepatic pedicle Glisson’s capsule in the liver hilar region share similar tumor anatomical and biological characteristics. Defining these two types as central-type intrahepatic cholangiocarcinoma,to distinguish them from peripheral-type intrahepatic cholangiocarcinoma,which lacks the aforementioned pathological and anatomical characteristics. This classification facilitates the conduct of homogeneous clinical studies and the establishment of a more effective surgical treatment system.

关键词

中央型肝内胆管癌 / 外周型肝内胆管癌 / 肿瘤微环境 / 神经侵犯 / 淋巴结转移

Key words

central-type intrahepatic cholangiocarcinoma / peripheral-type intrahepatic cholangiocarcinoma / tumor microenvironment / perineural invasion / lymphatic metastasis

引用本文

导出引用
李斌. 肝内胆管癌外科治疗研究焦点及分型治疗策略[J]. 中国实用外科杂志. 2026, 46(4): 472-479 https://doi.org/10.19538/j.cjps.issn1005-2208.2026.04.15
LI Bin. Research focus and subtype-specific treatment strategies for surgical treatment of intrahepatic cholangiocarcinoma[J]. Chinese Journal of Practical Surgery. 2026, 46(4): 472-479 https://doi.org/10.19538/j.cjps.issn1005-2208.2026.04.15
中图分类号: R6   

参考文献

[1]
Paradis V, Fukayma M, Park YN, et al. WHO classification of tumours- digestive system tumours[M]. 5th ed. Lyon: International Agency for Research on Cancer,2018:255-259.
[2]
Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma[J]. Eur J Surg Oncol, 2025, 51(2):107064. DOI: 10.1016/j.ejso.2023.107064.
[3]
Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype[J]. Eur J Cancer, 2022, 161:108-118. DOI: 10.1016/j.ejca.2021.11.023.
[4]
Tamandl D, Herberger B, Gruenberger B, et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2008, 15:2787-2794. DOI: 10.1245/s10434-008-0081-1.
[5]
Bridgewater J, Fletcher P, Palmer DH, et al. Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP study[J]. J Clin Oncol, 2022, 40:2048-2057. DOI: 10.1200/JCO.21.02568.
[6]
Zhang XF, Bagante F, Chen QY, et al. Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma[J]. Surgery, 2018, 163(5):1114-1120. DOI: 10.1016/j.surg.2018.01.001.
[7]
Choi JH, Thung SN. Recent advances in pathology of intrahepatic cholangiocarcinoma[J]. Cancers (Basel), 2024, 16(8):1537. DOI: 10.3390/cancers16081537.
[8]
Kosaka H, Kaibori M, Matsui K, et al. Investigation of a tumor location-specific therapeutic strategy for intrahepatic cholangiocarcinoma[J]. Asian Pac J Cancer Prev, 2021, 22(5):1485-1493. DOI: 10.31557/APJCP.2021.22.5.1485.
[9]
Endo Y, Moazzam Z, Lima HA, et al. The impact of tumor location on the value of lymphadenectomy for intrahepatic cholangiocarcinoma[J]. HPB (Oxford), 2023, 25(6):650-658. DOI: 10.1016/j.hpb.2023.02.013.
[10]
Sohn HJ, Kim H, Kim JR, et al. Predicting prognosis and evaluating the benefits of adjuvant chemotherapy depending on the tumor location in intrahepatic cholangiocarcinoma: focusing on the involvement of below 2nd bile duct confluence[J]. Ann Surg Treat Res, 2022, 102(5): 248-256. DOI: 10.4174/astr.2022.102.5.248.
[11]
Nakanuma Y, Klimstra DS, Komuta M, et al. WHO classification of tumours- digestive system tumours[M]. 5th ed. Lyon: International Agency for Research on Cancer,2018:254-259.
[12]
De Santis A, Zhu L, Tao J, et al. Molecular subtypes of intrahepatic cholangiocarcinoma[J]. Trends Mol Med, 2025, 31(8): 755-769. DOI: 10.1016/j.molmed.2025.01.008.
[13]
中国抗癌协会胆道肿瘤专业委员会. 中国抗癌协会胆道恶性肿瘤靶向及免疫治疗指南(2024简要版)[J]. 中国实用外科杂志, 2024, 44(9): 970-983. DOI: 10.19538/j.cjps.issn1005-2208.2024.09.02.
[14]
Zen Y. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities[J]. Hum Pathol, 2023, 132: 197-207. DOI: 10.1016/j.humpath.2022.06.001.
[15]
Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: an unusual tumor with distinctive clinical and pathological features[J]. Am J Med, 1965, 38: 241-256. DOI: 10.1016/0002-9343(65)90178-6.
[16]
Roa JC, Adsay NV, Arola J, et al. WHO classification of tumours - digestive system tumours[M]. 5th ed. Lyon: International Agency for Research on Cancer,2018: 290-291.
[17]
Brierley JD, Mary K, Gospodarowicz CW. Union for international cancer control(UICC). TNM classification of malignant tumours[M]. 8th ed. New York: John Wiley & Sons,Ltd,2017: 83-90.
[18]
Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States[J]. J Natl Cancer Inst, 2006, 98: 873-875. DOI: 10.1093/jnci/djj234.
[19]
Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)[J]. Nat Rev Gastroenterol Hepatol, 2016, 13: 261-280. DOI: 10.1038/nrgastro.2016.51.
[20]
Walter D, Ferstl P, Waidmann O, et al. Cholangiocarcinoma in Germany: epidemiologic trends and impact of misclassification[J]. Liver Int, 2019, 39:316-323. DOI: 10.1111/liv.13954.
[21]
Tan XX, Sivakumar S, Bednarsch J, et al. Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma[J]. Oncogene, 2021, 40(5):899-908. DOI: 10.1038/s41388-020-01578-4.
[22]
Meng XL, Lu JC, Zeng HY, et al. The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion[J]. Hepatol Int, 2023, 17(1):63-76. DOI: 10.1007/s12072-022-10445-1.
[23]
Liu Z, Luo C, Chen X, et al. Noninvasive prediction of perineural invasion in intrahepatic cholangiocarcinoma by clinicoradiological features and computed tomography radiomics based on interpretable machine learning: a multicenter cohort study[J]. Int J Surg, 2024, 110(2): 1039-1051. DOI: 10.1097/JS9.0000000000000881.
[24]
Silverman DA, Martinez VK, Dougherty PM, et al. Cancer-associated neurogenesis and nerve-cancer cross-talk[J]. Cancer Res, 2021, 81(6):1431-1440. DOI: 10.1158/0008-5472.CAN-20-2793.
[25]
Mantovani A, Marchesi F, Di Mitri D, et al. Macrophage diversity in cancer dissemination and metastasis[J]. Cell Mol Immunol, 2024, 21(11):1201-1214. DOI: 10.1038/s41423-024-01216-z.
[26]
Sposito C, Droz Dit Busset M, Virdis M, et al. The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: a review[J]. Eur J Surg Oncol, 2022, 48(1):150-159. DOI: 10.1016/j.ejso.2021.08.009.
[27]
Nevermann N, Bode J, Vischer M, et al. A surgical strategy for intrahepatic cholangiocarcinoma - the hilar first concept[J]. Langenbecks Arch Surg, 2023, 408(1): 296. DOI: 10.1007/s00423-023-03023-y.
[28]
Altaf A, Khalil M, Beliza A, et al. An easy-to-use online calculator to identify patients least likely to benefit from surgical resection of intrahepatic cholangiocarcinoma[J]. Surgery, 2025, 186: 109545. DOI: 10.1016/j.surg.2025.109545.
[29]
Sakamoto K, Ogawa K, Tamura K, et al. Prognostic role of the intrahepatic lymphatic system in liver cancer[J]. Cancers (Basel), 2023, 15(7): 2142. DOI: 10.3390/cancers15072142.
[30]
Karakousi T, Mudianto T, Lund AW. Lymphatic vessels in the age of cancer immunotherapy[J]. Nat Rev Cancer, 2024, 24(6):363-381. DOI: 10.1038/s41568-024-00681-y.
[31]
Li J, Wang QB, Liang YB, et al. Tumor-associated lymphatic vessel density is a reliable biomarker for prognosis of esophageal cancer after radical resection: a systemic review and meta-analysis[J]. Front Immunol, 2024, 15: 1453482. DOI: 10.3389/fimmu.2024.1453482.
[32]
Terada T, Nakanuma Y. Innervation of intrahepatic bile ducts and peribiliary glands in normal human livers, extrahepatic biliary obstruction and hepatolithiasis. An immunohistochemical study[J]. J Hepatol, 1989, 9(2): 141-148. DOI: 10.1016/0168-8278(89)90044-5.
[33]
TTzafriri AR, Garcia-Polite F, Keating J, et al. Morphometric analysis of the human common hepatic artery reveals a rich and accessible target for sympathetic liver denervation[J]. Sci Rep, 2022, 12(1): 1413. DOI: 10.1038/s41598-022-05475-6.
[34]
Smith C. Liver lymphatic anatomy and its role in systemic health and disease[J]. Lymphology, 2024, 57(1): 12-15. DOI: 10.55342/lymphology.2024.570102.
[35]
Kawarada Y, Das BC, Taoka H. Anatomy of the hepatic hilar area: the plate system[J]. J Hepatobiliary Pancreat Surg, 2000, 7(6): 580-586. DOI: 10.1007/s005340070007.
[36]
Hayashi S, Murakami G, Ohtsuka A, et al. Connective tissue configuration in the human liver hilar region with special reference to the liver capsule and vascular sheath[J]. J Hepatobiliary Pancreat Surg, 2008, 15(6): 640-647. DOI: 10.1007/s00534-008-1336-8.
[37]
Cantallops Vilà P, Ravichandra A, Agirre Lizaso A, et al. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma[J]. Hepatology, 2024, 79(4): 941-958. DOI: 10.1097/HEP.0000000000000206.
[38]
Affo S, Sererols-Viñas L, Garcia-Vicién G, et al. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma: insights into origins, heterogeneity, lymphangiogenesis, and peritoneal metastasis[J]. Am J Pathol, 2025, 195(3): 378-396. DOI:10.1016/j.ajpath.2024.07.009.
[39]
Yan J, Xiao G, Yang C, et al. Cancer-associated fibroblasts promote lymphatic metastasis in cholangiocarcinoma via the PDGF-BB/PDGFR-beta mediated paracrine signaling network[J]. Aging Dis, 2024, 15(1): 369-389. DOI: 10.14336/AD.2023.0420.
[40]
Cadamuro M, Brivio S, Mertens J, et al. Plateletderived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma[J]. J Hepatol, 2019, 70(4): 700-709. DOI: 10.1016/j.jhep.2018.12.004.
[41]
Cao Q, Yang J, Jiang L, et al. Single-cell analysis defines LGALS1+ fibroblasts that promote proliferation and migration of intrahepatic cholangiocarcinoma[J]. J Mol Cell Biol, 2024, 16(6): mjae023. DOI: 10.1093/jmcb/mjae023.
[42]
Zhang XF, Dong M, Pan YH, et al. Expression pattern of cancer-associated fibroblast and its clinical relevance in intrahepatic cholangiocarcinoma[J]. Hum Pathol, 2017, 65: 92-100. DOI: 10.1016/j.humpath.2017.04.014.
[43]
Dong ZR, Zhang MY, Qu LX, et al. Spatial resolved transcriptomics reveals distinct cross-talk between cancer cells and tumor-associated macrophages in intrahepatic cholangiocarcinoma[J]. Biomark Res, 2024, 12(1):100. DOI: 10.1186/s40364-024-00648-z.
[44]
Wang QL, Sun ZW, Guo JY, et al. Tumor-derived exosomal LINC01812 induces M2 macrophage polarization to promote perineural invasion in cholangiocarcinoma[J]. Cancer Lett, 2025, 617: 217596. DOI: 10.1016/j.canlet.2025.217596.
[45]
Ebrahim NAA, Soliman SMA, Othman MO, et al. Molecular mechanisms and clinical significance of perineural invasion in malignancies: the pivotal role of tumor-associated Schwann cells in cancer progression and metastasis[J]. Med Oncol, 2025, 42(5):171. DOI: 10.1007/s12032-025-02729-x.
[46]
Fu Y, Shen K, Wang H, et al. Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis[J]. Signal Transduct Target Ther, 2024, 9(1): 63. DOI: 10.1038/s41392-024-01761-z.
[47]
Zhao Y, Shen M, Wu L, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression?[J]. Cell Death Dis, 2023, 14(9): 587. DOI: 10.1038/s41419-023-06110-6.
[48]
Wu H, Li J, Yao R, et al. Focusing on the interplay between tumor-associated macrophages and tumor microenvironment: from mechanism to intervention[J]. Theranostics, 2025, 15(15): 7378-7408. DOI: 10.7150/thno.113727.
[49]
Franchis V, Petrungaro S, Pizzichini E, et al. Cholangiocarcinoma malignant traits are promoted by Schwann cells through TGF-βsignaling in a model of perineural invasion[J]. Cells, 2024, 13(5): 366. DOI: 10.3390/cells13050366.
[50]
Zu ZY, Zhang C, Shi JX, et al. Single-cell analysis reveals that GFAP+ dedifferentiated Schwann cells promote tumor progress in PNI- positive distal cholangiocarcinoma via lactate/HMGB1 axis[J]. Cell Death Dis, 2025, 16(1): 215. DOI: 10.1038/s41419-025-07543-x.
[51]
Gujarathi R, Peshin S, Zhang X, et al. Intrahepatic cholangiocarcinoma: insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel[J]. Hepatol Commun, 2025, 9(7): e0743. DOI: 10.1097/HC9.0000000000000743.
[52]
Wang CQ, Zhu Y, Sun HT, et al. Micro-lymphatic invasion impact prognosis of intrahepatic cholangiocarcinoma independent of lymph node metastasis and micro-vascular invasion[J]. Eur J Surg Oncol, 2025, 51(10): 110387. DOI: 10.1016/j.ejso.2025.110387.
[53]
Tan G, Wang WQ, Yuan T, et al. Machine learning prediction of perineural invasion in intrahepatic cholangiocarcinoma[J]. Eur J Surg Oncol, 2025, 51(9): 110203. DOI: 10.1016/j.ejso.2025.110203.
[54]
Ma ZJ, Xiang JX, Weiss M, et al. Long-term survivors after curative-intent resection for intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2024, 130(3): 443-452. DOI: 10.1002/jso.27739.
[55]
Martin-Serrano MA, Kepecs B, Torres-Martin M, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications[J]. Gut, 2023, 72(4): 736-748. DOI: 10.1136/gutjnl-2021-326514.
[56]
Schindler A, Denecke T, Seehofer D, et al. Intrahepatic cholangiocarcinoma as a unique subtype: key updates from current guidelines[J]. J Cancer Res Clin Oncol, 2025, 151(12): 305. DOI: 10.1007/s00432-025-06342-3.
[57]
Chen MC, Zhou XQ, Liu ZW, et al. Preoperative MRI prediction and molecular pathway study of perineural invasion in intrahepatic cholangiocarcinoma: insights from bioinformatics approach[J]. Eur J Surg Oncol, 2026, 52(1): 110546. DOI: 10.1016/j.ejso.2025.110546.
[58]
Wang Q, Qian X, Zhang Y, et al. Multi-regional radiomics for predicting microvascular invasion and lymph node metastasis in intrahepatic cholangiocarcinoma[J]. Clin Radiol, 2025, 88: 106979. DOI: 10.1016/j.crad.2025.106979.
[59]
Ke Q, Wang L, Lin ZG, et al. Prognostic value of lymph node dissection for intrahepatic cholangiocarcinoma patients with clinically negative lymph node metastasis: A multi-center study from China[J]. Front Oncol, 2021, 11: 585808. DOI: 10.3389/fonc.2021.585808.
[60]
Kim SH, Han DH, Choi GH, et al. Extent of lymph node dissection for accurate staging in intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2022, 26(1): 70-76. DOI: 10.1007/s11605-021-05039-5.
[61]
Sposito C, Ratti F, Cucchetti A, et al. Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma[J]. J Hepatol, 2023, 78(2): 356-363. DOI: 10.1016/j.jhep.2022.10.021.
[62]
Sha M, Cao J, Qin CL, et al. Impact of lymph node dissection for patients with clinically node-negative intrahepatic cholangiocarcinoma: a multicenter cohort study[J]. World J Oncol, 2024, 15(4): 579-591. DOI: 10.14740/wjon1895.
[63]
Lluís N, Asbun D, Wang JJ, et al. Lymph node dissection in intrahepatic cholangiocarcinoma: a critical and updated review of the literature[J]. J Gastrointest Surg, 2023, 27(12): 3001-3013. DOI: 10.1007/s11605-023-05696-8.
[64]
Zhang RY, Cao DY, Yang M, et al. Should lymphadenectomy be recommended in radical surgery of intrahepatic cholangiocarcinoma patients? A retrospective study[J]. J Cancer Res Clin Oncol, 2025, 151(3): 107. DOI: 10.1007/s00432-025-06148-3.
[65]
Nathan H, Wuithschick K, Goulet J, et al. Intrahepatic cholangiocarcinoma. AJCC cancer staging manual[M]. 8th ed. New York: Springer,2017:251-260.
[66]
Tanyi JL, Randall LM, Chambers SK, et al. A phase Ⅲ study of pafolacianine injection (OTL38) for intraoperative imaging of folate receptor-positive ovarian cancer (Study 006)[J]. J Clin Oncol, 2023, 41(2): 276-284. DOI: 10.1200/JCO.22.00291.
[67]
Ge Y, O'Shea DF. Review of clinically assessed molecular fluorophores for intraoperative image guided surgery[J]. Molecules, 2024, 29(24): 5964. DOI: 10.3390/molecules29245964.
[68]
Yang Z, Jiang X. Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis[J]. BMC Gastroenterol, 2023, 23(1): 122. DOI: 10.1186/s12876-023-02754-y.
[69]
Van Treeck BJ, Olave MC, Watkins RD, et al. Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma[J]. HPB (Oxford), 2024, 26(7): 938-948. DOI:10.1016/j.hpb.2024.04.003.
[70]
Maithel SK, Keilson JM, Cao HST, et al. NEO-GAP: A single-arm, phase Ⅱfeasibility trial of neoadjuvant gemcitabine,cisplatin,and nab-paclitaxel for resectable,high-risk intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2023, 30: 6558-6566. DOI:10.1245/s10434-023-13809-5.
[71]
Juengsamarn J, Sookthon C, Jeerapradit K, et al. Predictive MINT pathologic risk score for adjuvant chemotherapy in resected cholangiocarcinoma: a propensity score-matched multicenter study in Thailand[J]. JCO Glob Oncol, 2024, 10: e2400286. DOI: 10.1200/GO-24-00286.
[72]
Peng Y, Liang A, Chen Z, et al. The efficacy of adjuvant chemotherapy for curative resected biliary tract cancers: A systematic review and network meta-analysis of randomized clinical trials[J]. Int J Surg, 2025, 111(2): 2182-2194. DOI: 10.1097/JS9.0000000000002161.
[73]
Li XH, Zhou EL, Zhao CY, et al. Adjuvant chemotherapy combined with immunotherapy in patients with cholangiocarcinoma after radical resection[J]. Cancer Med, 2023, 12(24): 21742-21750. DOI:10.1002/cam4.6738.
[74]
Lo Prinzi F, Salani F, Rimini M, et al. Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: A large real-life worldwide population[J]. Oncologist, 2025, 30(3): oyae256. DOI:10.1093/oncolo/oyae256.
[75]
Cowzer D, Soares K, Walch H, et al. Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy[J]. J Natl Cancer Inst, 2025, 117(2): 279-286. DOI: 10.1093/jnci/djae202.
[76]
Im JH, Yu JI, Kim TH, et al. Combined high-dose radiotherapy with sequential gemcitabine-cisplatin based chemotherapy increase the resectability and survival in locally advanced unresectable intrahepatic cholangiocarcinoma: a multi-institutional cohort study[J]. Cancer Res Treat, 2024, 56(3): 838-846. DOI: 10.4143/crt.2023.886.

脚注

利益冲突 作者声明不存在利益冲突

基金

上海市科委“科技创新行动计划”医学创新研究专项项目(24Y12800504)
上海市科委“科技支撑”西医引导类项目(19411967000)

PDF(1346 KB)

Accesses

Citation

Detail

段落导航
相关文章

/